UPBD:NASDAQUpbound Group, Inc. Analysis
Data as of 2026-09-01 - not real-time
$18.30
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Upbound Group, Inc. trades at $18.30, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Over a rolling month the price has lost 15.6%. RSI sits at 38.0, which reads as approaching oversold, and MACD momentum is bearish. Watch $18.23 as support and $21.22 as the nearer resistance level.
Valuation screens as undervalued: a P/E of 12.4 sits below the sector average of 35.8. The average analyst target implies 54.4% above today's level. The 8.12% dividend yield looks stretched against payout coverage.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 40.8%, a beta of 1.48 and a maximum drawdown of 41.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.
Valuation screens as undervalued: a P/E of 12.4 sits below the sector average of 35.8. The average analyst target implies 54.4% above today's level. The 8.12% dividend yield looks stretched against payout coverage.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 40.8%, a beta of 1.48 and a maximum drawdown of 41.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.
Top Market Events
Upbound Group beat EPS but narrowed full-year revenue guidance as Brigit's 37% surge masks Acima's 2.Upbound Group UPBD is scheduled to announce Q2 earnings results on Thursday, July 30th, before market open.Bridget revenue jumps 37% and free cash flow soars to $84 million, while Acima faces an 11% GMV drop due to...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 19.09
- MACD momentum is negative
- 30-day price change of -15.6%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 12.4 versus sector average of 35.8
- Dividend yield of 8.12% looks stretched against payout coverage
- Trading below the 200-day average of 19.09
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 12.4 versus sector average of 35.8
- Dividend yield of 8.12% looks stretched against payout coverage
- Analyst targets imply +54.4% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth0.50%
Profit Margin1.90%
P/E Ratio12.4
ROE12.73%
ROA6.82%
Debt/Equity232.93
P/B Ratio1.5
Op. Cash Flow$425.5M
Free Cash Flow$1.6B
Industry P/E35.8
Technical Analysis
TrendNeutral
RSI38.0
Support$18.23
Resistance$21.22
MA 20$19.34
MA 50$20.15
MA 200$19.09
MACDBearish
VolumeDecreasing
Fear & Greed Index93.55
Valuation
Fair Value$322.40
Target Price$28.25
Upside/Downside54.37%
GradeUndervalued
TypeValue
Dividend Yield8.12%
Risk Assessment
Beta1.48
Volatility40.82%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.